SpringWorks
Bookmark
ShareCopied to clipboardSpringWorks is a company. It is a public company in Stamford, the United States. It was founded in 2017 and its current CEO is Saqib Islam. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Stamford
- country: United States
- employees: 368 people
- revenues: 191.6M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2017
- CEO: Saqib Islam
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about SpringWorks:
Dataset of stocks from SpringWorks:
SpringWorks is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Stamford and 3,456,808 companies in our database.
Talking Points
- SpringWorks Therapeutics - Unlocking Targeted Oncology
- We relentlessly pursue every possibility to create new cancer breakthroughs and power our approach with people who think hard, care hard, and act with urgency. %
- At SpringWorks, we bring tenacity to work every day because patients need answers now.
- SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology ...
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.